title: Survivin in ovary tumors.
abstract: BACKGROUND
  Survivin is a member of the inhibitor of apoptosis protein (IAP) family which are selectively overexpressed in human neoplasms, and its expression has been shown to be connected with cell proliferation. We analyzed survivin expression in ovarian epithelial neoplasms to evaluate its role in the development of ovarian tumors.
  
  
  METHODS
  Immunohistochemistry assays were conducted in 137 cases (48 ovarian carcinoma, 43 borderline ovarian carcinoma, 46 benign ovarian tumor and 20 samples of normal ovarian tissue of ovarian epithelial neoplasms. Histological types included serous (n = 68) and mucinous (n = 69) tumors. All tumors were reviewed histopathologically and classified according to the WHO criteria.
  
  
  RESULTS
  Survivin expression in the group of serous neoplasms was detected in 24.0% (6 of 25) of benign cases, in 60.0% (12 of 20) of borderline tumors, and 91.0% (24 of 47) of ovarian carcinomas. In the group of mucinous tumors, survivin expression was found in 33.5% (7 of 21) of benign cases, 43.5% (10 of 23) of borderline tumors, and 80.0% (20 of 25) of malignant tumors.
  
  
  CONCLUSIONS
  Our results demonstrate that survivin overexpression may play a crucial role in the development of epithelial ovarian neoplasms and be an important prognostic factor for the influence of survivin expression on epithelial ovarian cancers.
authors.forename: Danuta
authors.initials: D
authors.lastname: Plewka
authors.forename: Beata
authors.initials: B
authors.lastname: Jakubiec-Bartnik
authors.forename: Michał
authors.initials: M
authors.lastname: Morek
authors.forename: Edyta
authors.initials: E
authors.lastname: Bogunia
authors.forename: Marek
authors.initials: M
authors.lastname: Bienioszek
authors.forename: Hubert
authors.initials: H
authors.lastname: Wolski
authors.forename: Daniel
authors.initials: D
authors.lastname: Kotrych
authors.forename: Karolina
authors.initials: K
authors.lastname: Dziekan
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Seremak-Mrozikiewicz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Plewka
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism; D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin